HANDOK Inc.

KSE 002390.KS

HANDOK Inc. EBITDA for the year ending December 31, 2023: USD 26.93 M

HANDOK Inc. EBITDA is USD 26.93 M for the year ending December 31, 2023, a -32.17% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

HANDOK Inc. EBITDA for the year ending December 31, 2022 was USD 39.70 M, a -3.93% change year over year.
HANDOK Inc. EBITDA for the year ending December 31, 2021 was USD 41.33 M, a -9.66% change year over year.
HANDOK Inc. EBITDA for the year ending December 31, 2020 was USD 45.74 M, a -29.67% change year over year.
HANDOK Inc. EBITDA for the year ending December 31, 2019 was USD 65.05 M, a 107.17% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

KSE: 002390.KS

HANDOK Inc.

CEO	Mr. Young-Jin Kim M.B.A.
IPO Date	Jan. 4, 2000
Location	South Korea
Headquarters	132 Teheran-ro
Employees	938
Sector	Health Care
Industries Pharmaceuticals

Description

Handok Inc. operates as an integrated pharmaceutical company. The company provides ETC and OTC drugs, medical devices, and in-vitro diagnostics instruments and devices. It focuses on various therapeutic areas, such as oncology, diabetes and metabolic disorders, CNS orphan diseases, eye disorders, and other disease areas. The company also offers healthcare products comprising food supplements under the NatureSet and Culturelle brands; food and beverages; and medical nutrition products. Handok Inc. has a strategic collaboration agreement with AUM Biosciences Pte. Ltd. and CMG Pharmaceutical Co. Ltd. for the development, manufacturing, and commercialization of CHC2014, a pan-TRK inhibitor for cancer treatment. The company was formerly known as Handok Pharmaceuticals Co., Ltd and changed its name to Handok Inc. in July 2013. Handok Inc. was founded in 1954 and is based in Seoul, South Korea.

Key trends

Past 5 years